Table 1.
Summary of baseline and clinical characteristics in kidney transplant donors and recipients (total sample and categorized by delayed or prompt graft function).
| Total (n = 40) |
DGF (n = 18) |
Non-DGF (n = 22) | P value | |
|---|---|---|---|---|
| Donor | ||||
| Age (yr) | 51.2 ± 11.4 | 51.1 ± 13.4 | 51.2 ± 9.9 | 0.172 |
| Male gender | 26 (65) | 14 (78) | 12 (54.5) | 0.125 |
| Living donor | 11 (27.5) | 3 (16.7) | 8 (36.4) | 0.165 |
| Expanded criteria donors | 3 (7.5) | 1 (5.6) | 2 (9.1) | 0.541 |
| Serum creatinine (mg/dL) | 0.81 ± 0.18 | 0.85 ± 0.21 | 0.78 ± 0.16 | 0.318 |
| Donor-recipient | ||||
| HLA mismatches | 3.39 ± 1.24 | 3.38 ± 1.07 | 3.41 ± 1.46 | 0.941 |
| Cold ischemia time (h) | 12.1 ± 7.9 | 15.2 ± 7.8 | 9.6 ± 7.3 | 0.035* |
| Living donor | 2.8 ± 0.5 | 2.5 ± 0.5 | 3.0 ± 0.5 | 0.204 |
| Deceased donor | 16.2 ± 5.9 | 18.1 ± 5.1 | 14.1 ± 6.2 | 0.088 |
| Recipient | ||||
| Age (yr) | 49.2 ± 15.2 | 56.3 ± 10.9 | 43.3 ± 15.9 | 0.006* |
| Male gender | 26 (65) | 11 (61) | 15 (68) | 0.641 |
| Caucasian | 40 (100) | 18 (100) | 22 (100) | — |
| BMI (Kg/m2) | 24.8 ± 4.9 | 26.2 ± 4.4 | 23.6 ± 5.0 | 0.091 |
| Previous transplant | 2 (5) | 0 (0) | 2 (9.1) | |
| Time on dialysis (yr) | 4.4 ± 4.7 | 5.6 ± 6.2 | 3.4 ± 2.3 | 0.135 |
| Pretransplant therapy | ||||
| Dialysis | 38 (95) | 18 (100) | 20 (90.9) | 0.296 |
| Preemptive transplantation | 2 (5) | 0 (0) | 2 (9.1) | |
| Cause of kidney disease | ||||
| IgA nephropathy | 7 (17.5) | 2 (11.1) | 5 (22.7) | — |
| Glomerulonephritis | 6 (15.0) | 4 (22.2) | 2 (9.1) | — |
| Diabetic nephropathy | 5 (12.5) | 3 (16.7) | 2 (9.1) | — |
| Autosomal dominant polycystic kidney disease | 3 (7.5) | 3 (16.7) | 0 (0) | — |
| Unknown | 4 (10.0) | 1 (5.6) | 3 (13.6) | — |
| Others | 15 (37.5) | 5 (27.8) | 10 (45.5) | — |
| Peak PRA (%) | 5.5 ± 15.1 | 5.0 ± 15.0 | 5.9 ± 15.5 | 0.853 |
| 0 | 29 (72.5) | 14 (77.8) | 15 (68.2) | — |
| 1–25 | 8 (20.0) | 3 (16.7) | 5 (22.7) | — |
| 26–75 | 3 (7.5) | 1 (5.6) | 2 (9.0) | — |
| Current PRA (%) | 2.3 ± 8.6 | 3.1 ± 11.7 | 1.6 ± 4.9 | 0.585 |
| 0 | 34 (85) | 15 (83.3) | 19 (86.4) | — |
| 1–25 | 5 (12.5) | 2 (11.1) | 3 (13.6) | — |
| 26–50 | 1 (2.5) | 1 (5.6) | 0 (0) | — |
| Induction regimen | ||||
| Antithymocyte globulin (ATG-F) | 4 (10) | 1 (5.6) | 3 (13.6) | 0.613 |
| Basiliximab/daclizumab | 30 (75) | 14 (77.8) | 16 (72.7) | 0.789 |
| Immunosuppression at time of discharge | ||||
| Steroids | 38 (95.0) | 18 (100) | 20 (90.9) | 0.296 |
| Tacrolimus | 38 (95.0) | 17 (94.4) | 21 (95.5) | 0.886 |
| Cyclosporine A | 2 (0.05) | 1 (5.6) | 1 (5.6) | 0.884 |
Values are expressed as mean ± standard deviation or absolute numbers and percentages. Comparisons between continuous variables were done using parametric (t-test) or nonparametric (Mann-Whitney) tests; associations between categorical variables were analyzed using the χ 2 test and Fisher's exact test as appropriate; *P < 0.05.
Abbreviations: HLA: human leukocyte antigen; BMI: body mass index; PRA: panel reactive antibody.